OCUL Relative Valuation
OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCUL is overvalued; if below, it's undervalued.
Historical Valuation
Ocular Therapeutix Inc (OCUL) is now in the Overvalued zone, suggesting that its current forward PS ratio of 30.41 is considered Overvalued compared with the five-year average of -11.64. The fair price of Ocular Therapeutix Inc (OCUL) is between 2.21 to 7.08 according to relative valuation methord. Compared to the current price of 11.34 USD , Ocular Therapeutix Inc is Overvalued By 60.1%.
Relative Value
Fair Zone
2.21-7.08
Current Price：11.34
60.1%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
6.74
P/B
Median3y
19.64
Median5y
7.29
-8.40
FCF Yield
Median3y
-15.42
Median5y
-13.57
Competitors Valuation Multiple
The average P/S ratio for OCUL's competitors is 11.25, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL) exhibits a P/S ratio of 29.93, which is 166.05% above the industry average. Given its robust revenue growth of -27.59%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Ocular Therapeutix Inc (OCUL) currently overvalued or undervalued?
What is Ocular Therapeutix Inc (OCUL) fair value?
How does OCUL's valuation metrics compare to the industry average?
What is the current P/B ratio for Ocular Therapeutix Inc (OCUL) as of Jul 18 2025?
What is the current FCF Yield for Ocular Therapeutix Inc (OCUL) as of Jul 18 2025?
What is the current Forward P/E ratio for Ocular Therapeutix Inc (OCUL) as of Jul 18 2025?